// App-Quantinova.ai

2503 : Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.

Researchers

Presenter

  • Khanh Tu Do

Principal Investigators

  • Deborah Wilsker

  • Scott M Lawrence

  • Robert J. Kinders

  • Jerry Collins

  • Alice P. Chen

  • James H. Doroshow

  • Shivaani Kummar

  • Priya Balasubramanian

  • Jennifer Zlott

  • Woondong Jeong

Medical Centers

  • Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • National Cancer Institute, Bethesda, MDSAIC-Frederick, Inc., Frederick, MDNational Cancer Institute, Frederick, MD

  • Division of Cancer Treatment and Diagnosis, Natl Cancer Inst, Bethesda, MD

  • Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD

  • National Cancer Institute, Rockville, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • AZD-1775

  • MK1775

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01748825

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved